Zacks Investment Research on MSN8h
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...
The inclusion of cancer in the new research partnership suggests GSK's continuing interest in the therapy area, despite its divestment of its marketed oncology portfolio to Novartis. Being first ...
International biotechnology company GlaxoSmithKline is moving its ... step to strengthen its presence in the Greater Boston area. The research and development teams will relocate from Rockville ...
In this article, we are going to take a look at where GSK plc (NYSE:GSK ... a wide range of companies that provide patient care, research and development of new medicines, and design, manufacture ...
Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...
In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...
Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90. The company’s shares opened today at p1,443. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback